Two studies from Tetsuya Isaka et al 24 and Masaya Yotsukura et al 25 have reported patients with EGFR mutations in operable early-stage lung adenocarcinoma had a better RFS because of its higher incidence of lepidic growth pattern, adenocarcinoma in situ and minimally invasive adenocarcinoma, which rarely recur after resection of the lung when compared with those without EGFR mutations, but there was no significant difference in OS. The gene discussed is EGFR; the disease is adenocarcinoma in situ.